The Role of Purinergic P2X7 Receptor in Inflammation and Cancer: Novel Molecular Insights and Clinical Applications
- PMID: 35267424
- PMCID: PMC8909580
- DOI: 10.3390/cancers14051116
The Role of Purinergic P2X7 Receptor in Inflammation and Cancer: Novel Molecular Insights and Clinical Applications
Abstract
The purinergic P2X7 receptor (P2X7R) is a transmembrane protein whose expression has been related to a variety of cellular processes, while its dysregulation has been linked to inflammation and cancer. P2X7R is expressed in cancer and immune system cell surfaces. ATP plays a key role in numerous metabolic processes due to its abundance in the tumour microenvironment. P2X7R plays an important role in cancer by interacting with ATP. The unusual property of P2X7R is that stimulation with low doses of ATP causes the opening of a permeable channel for sodium, potassium, and calcium ions, whereas sustained stimulation with high doses of ATP favours the formation of a non-selective pore. The latter effect induces a change in intracellular homeostasis that leads to cell death. This evidence suggests that P2X7R has both pro- and anti-tumour proprieties. P2X7R is increasingly recognised as a regulator of inflammation. In this review, we aimed to describe the most relevant characteristics of P2X7R function, activation, and its ligands, while also summarising the role of P2X7R activation in the context of inflammation and cancer. The currently used therapeutic approaches and clinical trials of P2X7R modulators are also described.
Keywords: ATP; BzATP; P2X7 receptor; P2X7R; colon cancer; immune system; infection; inflammation; malignant pleural mesothelioma; melanoma; tumour microenvironment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells.Mol Cancer. 2015 Nov 25;14:203. doi: 10.1186/s12943-015-0472-4. Mol Cancer. 2015. PMID: 26607222 Free PMC article.
-
Purinergic P2X7 Receptor: A Cation Channel Sensitive to Tumor Microenvironment.Recent Pat Anticancer Drug Discov. 2019;14(1):32-38. doi: 10.2174/1574892814666190116122256. Recent Pat Anticancer Drug Discov. 2019. PMID: 30652649 Review.
-
P2X7 targeting inhibits growth of human mesothelioma.Oncotarget. 2016 Aug 2;7(31):49664-49676. doi: 10.18632/oncotarget.10430. Oncotarget. 2016. PMID: 27391069 Free PMC article.
-
Activation of endothelial NO synthase and P2X7 receptor modification mediates the cholinergic control of ATP-induced interleukin-1β release by mononuclear phagocytes.Front Immunol. 2023 Mar 9;14:1140592. doi: 10.3389/fimmu.2023.1140592. eCollection 2023. Front Immunol. 2023. PMID: 36969210 Free PMC article.
-
Molecular probes for P2X7 receptor studies.Curr Med Chem. 2007;14(14):1505-23. doi: 10.2174/092986707780831023. Curr Med Chem. 2007. PMID: 17584060 Review.
Cited by
-
Two Single Nucleotide Polymorphisms in the Purinergic Receptor P2X7 Gene Are Associated with Disease Severity in Multiple Sclerosis.Int J Mol Sci. 2022 Dec 6;23(23):15381. doi: 10.3390/ijms232315381. Int J Mol Sci. 2022. PMID: 36499708 Free PMC article.
-
Kunitz-Type Peptides from Sea Anemones Protect Neuronal Cells against Parkinson's Disease Inductors via Inhibition of ROS Production and ATP-Induced P2X7 Receptor Activation.Int J Mol Sci. 2022 May 4;23(9):5115. doi: 10.3390/ijms23095115. Int J Mol Sci. 2022. PMID: 35563513 Free PMC article.
-
[P2X7R promotes migration and invasion of Lewis lung cancer cells by activating the AKT signaling pathway].Nan Fang Yi Ke Da Xue Xue Bao. 2022 Oct 20;42(10):1495-1502. doi: 10.12122/j.issn.1673-4254.2022.10.08. Nan Fang Yi Ke Da Xue Xue Bao. 2022. PMID: 36329583 Free PMC article. Chinese.
-
P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma.Sci Rep. 2023 May 24;13(1):8435. doi: 10.1038/s41598-023-35712-5. Sci Rep. 2023. PMID: 37225786 Free PMC article.
-
Purines and purinergic receptors in primary tumors of the central nervous system.Purinergic Signal. 2024 Oct 1. doi: 10.1007/s11302-024-10053-8. Online ahead of print. Purinergic Signal. 2024. PMID: 39352574
References
-
- De Marchi E., Orioli E., Pegoraro A., Sangaletti S., Portararo P., Curti A., Colombo M.P., Di Virgilio F., Adinolfi E. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene. 2019;38:3636–3650. doi: 10.1038/s41388-019-0684-y. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources